Guidance for identification and treatment of individuals with attention deficit/hyperactivity disorder and autism spectrum disorder based upon expert consensus
- PMID: 32448170
- PMCID: PMC7247165
- DOI: 10.1186/s12916-020-01585-y
Guidance for identification and treatment of individuals with attention deficit/hyperactivity disorder and autism spectrum disorder based upon expert consensus
Abstract
Background: Individuals with co-occurring hyperactivity disorder/hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) can have complex presentations that may complicate diagnosis and treatment. There are established guidelines with regard to the identification and treatment of ADHD and ASD as independent conditions. However, ADHD and ASD were not formally recognised diagnostically as co-occurring conditions until the Diagnostic and Statistical Manual of Mental Disorders 5 (DSM-5) was published in 2013. Hence, awareness and understanding of both conditions when they co-occur is less established and there is little guidance in the clinical literature. This has led to uncertainty among healthcare practitioners when working with children, young people and adults who present with co-existing ADHD and ASD. The United Kingdom ADHD Partnership (UKAP) therefore convened a meeting of professional experts that aimed to address this gap and reach expert consensus on the topic that will aid healthcare practitioners and allied professionals when working with this complex and vulnerable population.
Method: UK experts from multiple disciplines in the fields of ADHD and ASD convened in London in December 2017. The meeting provided the opportunity to address the complexities of ADHD and ASD as a co-occurring presentation from different perspectives and included presentations, discussion and group work. The authors considered the clinical challenges of working with this complex group of individuals, producing a consensus for a unified approach when working with male and female, children, adolescents and adults with co-occurring ADHD and ASD. This was written up, circulated and endorsed by all authors.
Results: The authors reached a consensus of practical recommendations for working across the lifespan with males and females with ADHD and ASD. Consensus was reached on topics of (1) identification and assessment using rating scales, clinical diagnostic interviews and objective supporting assessments; outcomes of assessment, including standards of clinical reporting; (2) non-pharmacological interventions and care management, including psychoeducation, carer interventions/carer training, behavioural/environmental and Cognitive Behavioural Therapy (CBT) approaches; and multi-agency liaison, including educational interventions, career advice, occupational skills and training, and (3) pharmacological treatments.
Conclusions: The guidance and practice recommendations (Tables 1, 4, 5, 7, 8 and 10) will support healthcare practitioners and allied professionals to meet the needs of this complex group from a multidisciplinary perspective. Further research is needed to enhance our understanding of the diagnosis, treatment and management of individuals presenting with comorbid ADHD and ASD.
Keywords: Assessment; Autism spectrum disorder (ASD); Comorbidity; Consensus; Education; Guidance; Interventions; Occupation; Psychiatry; Psychology; School; Treatment; hyperactivity disorder/hyperactivity disorder (ADHD).
Conflict of interest statement
In the last 5 years, SY has received honoraria for consultancy and educational talks years from Janssen, HB Pharma and/or Shire. She is an author of the RATE Scales [70]; the Diagnostic Autism Spectrum Interview (DASI) [78]; the ADHD Child Evaluation (ACE) [82] and ACE+ for adults [83]; Helping Children with ADHD CBT programme [101]; The Star Programme for children with cognitive, behavioural, emotional and social problems [102, 103]; and R&R2 for ADHD Youths and Adults [113]. PH has received honoraria for consultancy and educational talks in the last 5 years from Shire, Janssen and Flynn. He has acted as an expert witness for Lilly. PB has received honoraria for educational talks from Shire and research grants from Action Medical Research and the UK Tuberous Sclerosis Association for research on ASD and ADHD. In addition, SY, PB, WC, PH, FOR, PR, NS and EW are affiliated on a full-time basis with consultancy firms/private practices. The remaining authors have no disclosures.
Similar articles
-
Females with ADHD: An expert consensus statement taking a lifespan approach providing guidance for the identification and treatment of attention-deficit/ hyperactivity disorder in girls and women.BMC Psychiatry. 2020 Aug 12;20(1):404. doi: 10.1186/s12888-020-02707-9. BMC Psychiatry. 2020. PMID: 32787804 Free PMC article.
-
Identification and treatment of offenders with attention-deficit/hyperactivity disorder in the prison population: a practical approach based upon expert consensus.BMC Psychiatry. 2018 Sep 4;18(1):281. doi: 10.1186/s12888-018-1858-9. BMC Psychiatry. 2018. PMID: 30180832 Free PMC article.
-
Guidelines for identification and treatment of individuals with attention deficit/hyperactivity disorder and associated fetal alcohol spectrum disorders based upon expert consensus.BMC Psychiatry. 2016 Sep 22;16(1):324. doi: 10.1186/s12888-016-1027-y. BMC Psychiatry. 2016. PMID: 27655132 Free PMC article.
-
Autism Spectrum Disorders and ADHD: Overlapping Phenomenology, Diagnostic Issues, and Treatment Considerations.Curr Psychiatry Rep. 2019 Mar 22;21(5):34. doi: 10.1007/s11920-019-1020-5. Curr Psychiatry Rep. 2019. PMID: 30903299 Review.
-
Identification and treatment of individuals with attention-deficit/hyperactivity disorder and substance use disorder: An expert consensus statement.World J Psychiatry. 2023 Mar 19;13(3):84-112. doi: 10.5498/wjp.v13.i3.84. eCollection 2023 Mar 19. World J Psychiatry. 2023. PMID: 37033892 Free PMC article. Review.
Cited by
-
Improving Diagnostic Procedures in Autism for Girls and Women: A Narrative Review.Neuropsychiatr Dis Treat. 2024 Mar 7;20:505-514. doi: 10.2147/NDT.S372723. eCollection 2024. Neuropsychiatr Dis Treat. 2024. PMID: 38469208 Free PMC article. Review.
-
Lisdexamfetamine-Induced Psychosis in a Patient With a Neurodevelopmental Disorder.Cureus. 2024 Jan 31;16(1):e53349. doi: 10.7759/cureus.53349. eCollection 2024 Jan. Cureus. 2024. PMID: 38435908 Free PMC article.
-
Potential Mechanisms Underlying Suicidality in Autistic People with Attention Deficit/Hyperactivity Disorder: Testing Hypotheses from the Interpersonal Theory of Suicide.Autism Adulthood. 2024 Mar 1;6(1):9-24. doi: 10.1089/aut.2022.0042. Epub 2024 Feb 28. Autism Adulthood. 2024. PMID: 38435325
-
Detecting Autism Spectrum Disorder and Attention Deficit Hyperactivity Disorder Using Multimodal Time-Frequency Analysis with Machine Learning Using the Electroretinogram from Two Flash Strengths.J Autism Dev Disord. 2024 Feb 23. doi: 10.1007/s10803-024-06290-w. Online ahead of print. J Autism Dev Disord. 2024. PMID: 38393437
-
A US national update of health condition prevalence among privately-insured autistic adults.J Comp Eff Res. 2024 Mar;13(3):e230051. doi: 10.57264/cer-2023-0051. Epub 2024 Jan 31. J Comp Eff Res. 2024. PMID: 38294339 Free PMC article.
References
-
- Polanczyk G, De Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry. 2007;164(6):942–948. - PubMed
-
- Hollingdale J, Woodhouse E, Young S, Fridman A, Mandy W. Autistic spectrum disorder symptoms in children and adolescents with attention deficit/hyperactivity disorder: a meta-analytical review. Psychol Med, BMC Psychiatry. 19:404. 10.1186/s12888-019-2284-3.
-
- Diagnostic and statistical manual of mental disorders. 5th ed (DSM-5). Arlington, VA: American Psychiatric Association. 2013.
-
- Spencer TJ, Biederman J, Mick E. Attention-deficit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology. J Pediatr Psychol. 2007;32(6):631–642. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
